Examining Clinical Trial Participation for Small Cell Lung Cancer Patients
Not yet recruiting
- Conditions
- Small Cell Lung Cancer
- Registration Number
- NCT05769504
- Lead Sponsor
- Power Life Sciences Inc.
- Brief Summary
Clinical study participation percentages haven't always been fully representative of a given demographic.
The goal is to find out which aspects of a clinical trial may make it more difficult for patients to take part or see it through.
The data will be evaluated through different demographic lenses and identify trends that could help improve the experience of future small cell lung cancer patients during clinical trials.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 500
Inclusion Criteria
- Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed.
- Participant has a diagnosis of small cell lung cancer.
- Willing and able to comply with scheduled visits, treatment schedule, laboratory tests and other requirements of the study.
Exclusion Criteria
- Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent.
- Pregnant or lactating woman
- Known medical condition that, in the investigator's opinion, would increase the risk associated with study participation or study drug(s) administration or interfere with the interpretation of safety results
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Rate of patients who decide to enroll in a small cell lung cancer clinical study. 3 months Number of small cell lung cancer patients who remain in clinical trial until completion. 12 months
- Secondary Outcome Measures
Name Time Method